Morgan Stanley raised the price target for the Johnson & Johnson (NYSE:JNJ) stock to “an Overweight”. The rating was released on May 28, 2021. We previously noted in another research note published on April 28, 2020 by UBS that downgraded the stock from a Buy to a Neutral with a price target of $160 for JNJ stock. The research report from BofA/Merrill has upgraded the stock from Neutral to Buy, with a price target set at $175. The stock was initiated by Citigroup, who disclosed in a research note on March 05, 2020, to Buy and set the price objective to $163. In their research brief published December 19, 2019, Barclays analysts upgraded the Johnson & Johnson stock from Equal Weight to Overweight with a price target of $173.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Johnson & Johnson (NYSE:JNJ) dipped -0.60% to close Tuesday’s market session at $167.97, lower as compared to yesterday’s close. The stock price fluctuated between $166.99 and $168.86 throughout the trading session with the volume trading being 6079248 shares, which represented a significant variation when compared to the three months average volume of 7.04 million shares. The firm’s stock price fluctuated 2.41% within the last five trades and 1.21% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 7.33% in the last 6 months and 2.80% was added to its value over the previous 3 months. JNJ stock is trading at a margin of 2.02%, 0.91% and 6.50% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, JNJ deals in the Healthcare domain. The stock is trading -3.27 percent below its 52-week high and 25.68 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 17.25. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Johnson & Johnson’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 20.70 percent and the profit margin is 17.90 percent, and the company has reported a gross margin of 66.40 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $434.43 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Johnson & Johnson (NYSE:JNJ) is 29.67. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 16.12. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 5.16 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 6.71, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.10 percent of Johnson & Johnson shares are owned by insiders, and 69.00 percent are held by financial institutions. Sneed Michael E, the EVP, Global Corp Aff & COO at Johnson & Johnson (JNJ) has sold 54,662 shares of firm on Dec 09 at a price of $152.93 against the total amount of $8.36 million. In another inside trade, Wengel Kathryn E, EVP, Chief GSC Officer of Johnson & Johnson (NYSE:JNJ) sold 16,115 shares of the firm on Sep 02 for a total worth of $2.47 million at a price of $153.52. An inside trade which took place on Jul 28, EVP, WW Chair, Medical Devices of Johnson & Johnson McEvoy Ashley sold 29,000 shares of firm against total price of $4.28 million at the cost of $147.47 per share.